Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development

Oragenics Inc. (NYSE American: OGEN) has filed its Annual Report on Form 10-K for the year ended December 31, 2025, accompanied by a shareholder update detailing operational, clinical, and financial progress. The clinical-stage biotechnology company reported achieving several key milestones in 2025, including the restoration of its compliance with NYSE American listing standards, which provides stability for continued operations and investor confidence.

The company successfully completed a capital raise of $16.5 million, providing essential funding to advance its research and development programs. A significant operational shift involved transitioning its drug manufacturing to a U.S.-based facility, which streamlines production and supports regulatory requirements for future clinical trials. The company’s primary focus remains the advancement of ONP-002, its lead candidate being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury using proprietary intranasal delivery technology.

According to the update, Oragenics has made early progress in 2026 toward initiating a Phase IIa clinical trial for ONP-002 in Australia. The company’s strategic priorities for the coming period include patient enrollment for these trials, advancing regulatory discussions in the United States to pave the way for subsequent Phase 2b trials, and expanding its pipeline of central nervous system (CNS) therapeutics. The intranasal delivery platform underlying ONP-002 has potential applications for other neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, representing a broader therapeutic strategy.

The filing of the Form 10-K provides investors with a comprehensive financial and operational overview for the fiscal year. For more detailed information, the full press release is available online. The company’s broader corporate communications and news updates are managed through specialized platforms, including TinyGems.com, a communications service focused on small-cap and mid-cap companies. Further information about Oragenics and its development programs can be found on the company’s website at oragenics.com.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development.

The post Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development appeared first on citybuzz.